Latest News and Press Releases

Den tabletbaserede allergivaccine GRAZAX® når det primære mål i et amerikansk klinisk studie med voksne græspollenallergikere. ALKs strategiske samarbejdspartner i Nordamerika, Schering-Plough, har...

The investigational sublingual allergy immunotherapy tablet (GRAZAX®) meets primary endpoint in a study of adult subjects with a history of grass pollen allergies. Schering-Plough Corporation, ALK's...

Sundhedsmyndighederne i 27 europæiske lande har godkendt GRAZAX® som en sygdomsmodificerende allergibehandling. GRAZAX® er dermed den eneste godkendte tabletbehandling mod græspollenallergi med en...

Authorities in 27 European countries have approved GRAZAX® as a disease modifying allergy treatment. GRAZAX® is now the only registered tablet treatment against grass pollen allergy with documented...

(unaudited) Financial performance in the six months ended June 30, 2009 (Comparative figures for the same period last year are shown in brackets) - Sales growth continued in Q2 and organic growth in...

(urevideret) Økonomiske resultater for perioden (Sammenligningstal for samme periode sidste år er anført i parentes) - Salgsvæksten fortsatte i andet kvartal, og den organiske vækst i vaccinesalget...

On Tuesday, August 18, 2009, ALK releases its interim report for the six months ended June 30, 2009. ALK will hold a conference call for analysts and investors that day at 2.30 p.m. (CET) at which...

Tirsdag den 18. august 2009 offentliggør ALK delårsrapport for første halvår (Q2) 2009. ALK afholder samme dag kl. 14.30 (CET) en telefonkonference for analytikere og investorer, hvor adm. direktør...

The clinical benefits of ALK's allergy immunotherapy tablet (AIT) for grass allergy, GRAZAX®, are sustained after completion of treatment. A follow-up study covering the first year after treatment...

ALK's house dust mite allergy immunotherapy tablet (AIT) has a significant positive clinical effect in asthma patients. This is the conclusion from a large Phase II/III clinical study (MT-02)...